澳门大阳城集团2138网站|主頁-欢迎您!

ENGLISH

检测到您当前使用浏览器版本过于老旧,会导致无法正常浏览网站;请您使用电脑里的其他浏览器如:360、QQ、搜狗浏览器的极速模式浏览,或者使用谷歌、火狐等浏览器。

下载Firefox
夏宁邵教授博导

邮  箱:nsxia@xmu.edu.cn

职称/职务:教授 博士生导师

联系方式:0592-2183111

  • 个人简介
  • 科研领域
  • 代表性成果

1995-2002年,澳门大阳城集团澳门大阳城集团2138网站,副教授;
2002年至今,澳门大阳城集团澳门大阳城集团2138网站,教授、博导;
2005年至今,国家传染病诊断试剂与疫苗工程技术研究中心主任;
2011-2021年,澳门大阳城集团公共卫生学院,院长。
Associate Professor, School of Life Sciences, Xiamen University, 1995-2002;
Professor, School of Life Sciences, Xiamen University, 2002 to Present;
Director, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, 2005 to Present;
Dean, School of Public Health, Xiamen University, 2011-2021.

从事传染病防控的基础研究、应用基础研究、转化医学研究,诊断试剂、疫苗、抗体研发,涉及病毒性肝炎、艾滋病、流感、手足口病、结核、人乳头瘤病毒相关疾病等。主持研制出全球首个戊肝疫苗、首个国产宫颈癌疫苗、新一代国际“金标准”戊肝诊断试剂、全球首个乙肝核心抗体定量试剂、全球首个艾滋尿液自检试剂;第二代九价宫颈癌疫苗进入III期临床试验、新型水痘减毒活疫苗(敲除毒力基因ORF7)进入II期临床试验,鼻喷流感病毒载体新冠肺炎疫苗已完成II期临床试验,正在菲律宾等国开展海外III期临床试验;向全球疫苗巨头葛兰素史克、赛诺菲巴斯德授权新一代宫颈癌疫苗和新型轮状病毒疫苗专利技术。

代表性论文(# co-first author, * Corresponding author):

1. Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Yu H#, Lin Y, Wu YY, He MZ, Huang Y, Jiang YC, Sun H, Zha ZH, Yang HW, Huang QZ, Zhang DQ, Chen ZQ, Ye XZ, Han JL, Yang LS, Liu C, Que YQ, Fang MJ, Gu Y, Zhang J, Luo W, Zhou ZH*, Li SW*, Cheng T*, Xia NS*. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host & Microbe. 2021. (IF=15.923)
2. He MZ#, Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Zha ZH, Lin Y, Yang LS, Huang Y, Ye XZ, Li SX, Hou WH, Wu YT, Han JL, Liu DX, Li ZK, Chen ZQ, Yu H, Que YQ, Wang YB, Yan XD, Zhang J, Gu Y, Zhou ZH*, Cheng T*, Li SW*, Xia NS*. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host & Microbe. 2020;27(2):249-+. (IF=15.923)
3. Wang W#, Zheng QB#, Pan DQ#, Yu H#, Fu WK, Liu J, He MZ, Zhu R,Cai YZ,Huang Y,Zha ZH,Chen ZQ,Ye XZ,Han JL,Que YQ,Wu T,Zhang J,Li SW*,Zhu H*,Zhou ZH*,Cheng T*,Xia NS*.Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids. Nature Microbiology. 2020;10.1038/s41564-020-0785-y. (IF=15.54)
4. Wang DN#, Liu XL#, Wei MX#, Qian CY, Song S, Chen J, Wang ZP, Xu Q, Yang YR, He MZ, Chi X, Huang SW, Li TT, Kong ZB, Zheng QB, Yu H, Wang YB, Zhao QJ, Zhang J, Xia NS*, Gu Y*, Li SW*. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications. 2020;11(1). (IF=12.121)
5. Wen GP#, He LL#, Tang ZM#, Wang SL#, Zhang X, Chen YZ, Lin XH, Liu C, Chen JX, Ying D, Chen ZH, Wang YB, Luo WX, Huang SJ, Li SW, Zhang J, Zheng ZZ*, Zhu J*, Xia NS*. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications. 2020;11(1). (IF=12.121)
6. Zhang YL#, Wang SJ#, Wu YT#, Hou WH#, Yuan LZ#, Sheng CG#, Wang J, Ye JH, Zheng QB, Ma J, Xu JJ, Wei M, Li ZL, Nian S, Xiong HL, Zhang L, Shi Y, Fu BR, Cao JL, Yang CL, Li ZY, Yang T, Liu L, Yu H, Hu JD, Ge SX, Chen YX, Zhang TY, Zhang J, Cheng T*, Yuan Q*, Xia NS*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. (IF=12.13)
7. Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Mo XB, Li TL, Kang XZ, Zhao JH, Yin B, Zhao X, Huang CH, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nature Communications. 2019;10(1):3192. (IF=11.878)
8. Liu X#, Liu C#, Zheng ZZ#, Chen SY, Pang X, Xiang XC, Tang JX, Ren E, Chen YZ, You M, Wang XY, Chen XY, Luo WX*, Liu G*, Xia NS*. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Adv Mater. 2019;31(17). (IF=25.809)
9. Yuan L#, Jiang J#, Liu X#, Zhang Y, Zhang L, Xin J, Wu K, Li X, Cao J, Guo X, Shi D, Li J, Jiang L, Sun S, Wang T, Hou W, Zhang T, Zhu H, Zhang J, Yuan Q, Cheng T*, Li J*, Xia N*. HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut. 2019;68(11):2044-56.. (IF=17.943)
10. Zhang T-Y#, Guo X-R#, Wu Y-T#, Kang X-Z, Zheng Q-B, Qi R-Y, Chen B-B, Lan Y, Wei M, Wang S-J, Xiong H-L, Cao J-L, Zhang B-H, Qiao X-Y, Huang X-F, Wang Y-B, Fang M-J, Zhang Y-L, Cheng T, Chen Y-X, Zhao Q-J, Li S-W, Ge S-X, Chen P-J, Zhang J*, Yuan Q*, Xia N-S*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020;69(2):343-54. (IF=17.943)
11. Qiao Y-L#*, Wu T#, Li R-C#, Hu Y-M#, Wei L-H#, Li C-G#, Chen W#, Huang S-J, Zhao F-H, Li M-Q, Pan Q-J, Zhang X, Li Q, Hong Y, Zhao C, Zhang W-H, Li Y-P, Chu K, Li M, Jiang Y-F, Li J, Zhao H, Lin Z-J, Cui X-L, Liu W-Y, Li C-H, Guo D-P, Ke L-D, Wu X, Tang J, Gao G-Q, Li B-Y, Zhao B, Zheng F-X, Dai C-H, Guo M, Zhao J, Su Y-Y, Wang J-Z, Zhu F-C, Li S-W, Pan H-R, Li Y-M, Zhang J*, Xia N-S*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145-53.(IF=10.211)
12. Zheng Q,# Jiang J#, He M#, Zheng Z#, Yu H, Li T, Xue W, Tang Z, Ying D, Li Z, Song S, Liu X, Wang K, Zhang Z, Wang D, Wang Y, Yan X, Zhao Q, Zhang J, Gu Y*, Li S*, Xia N*. Viral neutralization by antibody-imposed physical disruption. Proc Natl Acad Sci U S A. 2019;116 (52) :26933-26940. (IF=9.58)
13. Zheng QB#, Zhu R#, Xu LF#, He MZ#, Yan XD#, Liu DX, Yin ZC, Wu YT, Li YC, Yang LS, Hou WH, Li SX, Li ZZ, Chen ZQ, Li ZH, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS*, Cheng T*, Li SW*, Xia NS*. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology. 2019;4(1):124-+. (IF=14.174)
14. Li ZH#, Song S#, He MZ#, Wang DN, Shi JJ, Liu XL, Li YB, Chi X, Wei SP, Yang YR, Wang ZP, Li JJ, Qian HL, Yu H, Zheng QB, Yan XD, Zhao QJ, Zhang J, Gu Y*, Li SW*, Xia NS*. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications. 2018;9. (IF=12.353)
15. Zhu R#, Xu LF#, Zheng QB#, Cui YX#, Li SW#, He MZ, Yin ZC, Liu DX, Li SX, Li ZZ, Chen ZQ, Yu H, Que YQ, Liu C, Kong Z, Zhang JB, Baker TS, Yan XD*, Zhou ZH*, Cheng T*, Xia NS*. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances. 2018;4(9). (IF=11.511)
16. Shen CG, Chen JY, Li R, Zhang MY, Wang GS, Stegalkina S, Zhang LM, Chen J, Cao JL, Bi XJ, Anderson SF, Alefantis T, Zhang MW, Cai XY, Yang KY, Zheng QB, Fang MJ, Yu H, Luo WX, Zheng ZZ, Yuan Q, Zhang J, Shih JWK, Kleanthous H, Chen HL, Chen YX*, Xia NS*. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine. 2017;9(412). (IF=16.761)
17. Xu LF, Zheng QB, Li SW, He MZ, Wu YT, Li YC, Zhu R, Yu H, Hong QY, Jiang J, Li ZZ, Li SX, Zhao H, Yang LS, Hou WH, Wang W, Ye XZ, Zhang J, Baker TS, Cheng T*, Zhou ZH, Yan XD*, Xia NS*. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nature Communications. 2017;8. (IF=12.124)
18. Tian DY, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS*, McLellan JS*, Graham BS*. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications. 2017;8. (IF=12.124)
19. Zhang TY, Yuan Q*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JWK, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016;65(4):658-71. (IF=14.66)
20. Fan R, Sun J, Yuan Q, Xie Q, Bai XF, Ning Q, Cheng J, Yu YY, Niu JQ, Shi GF, Wang H, Tan DM, Wan MB, Chen SJ, Xu M, Chen XY, Tang H, Sheng JF, Lu FM, Jia JD, Zhuang H, Xia N*, Hou J*, Chronic Hepatitis BS. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65(2):313-20. (IF=14.66)
21. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, Yuan Q, Li P-C, Huang Q, Colonno R, Jia J, Hou J, McCrae MA, Gao Z*, Ren H*, Xia N*, Zhuang H, Lu F*. Serum Hepatitis B Virus Rna Is Encapsidated Pregenome Rna That May Be Associated with Persistence of Viral Infection and Rebound. Journal of Hepatology; 2016, 65: 700-10. (IF=10.59)
22. Zhang J*, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JWK, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. N Engl J Med. 2015;372(10):914-22. (IF= 55.873)
23. Gu Y, Tang XH, Zhang X, Song CL, Zheng MH, Wang KH, Zhang J, Ng MH, Hew CL, Li SW*, Xia NS*, Sivaraman J*. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 2015;25(5):604-20. (IF=12.413)
24. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY,Zhang J*,Kao J-H,Chen D-S,Chen PJ*Xia NS*: Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 2013, 62(1):182-184. (IF=10.111)
25. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, Xia NS∗. Safety of hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology, 2012, 55(6): 2038, doi: 10.1002/ hep.25522 (IF=10.885)
26. Cheng-Hao Huang, Quan Yuan, Pei-Jer Chen, Ya-Li Zhang, Chang-Rong Chen, Qing-Bing Zheng, Shiou-Hwei Yeh, Hai Yu, Yu Xue, Yi-Xin Chen, Ping-Guo Liu, Sheng-Xiang Ge, Jun Zhang*, Ning-Shao Xia*. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. Journal of Hepatology 2012 vol.57(4):720-729 (IF=9.334)
27. Xin Geng, Chenghao Huang, Yan Qin, Janet E. McCombs, Quan Yuan, Brian L. Harry, Amy E. Palmer. Ning-Shao Xia*, and Ding Xue*. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natl Acad Sci U S A. 2012 Oct 22 (IF=9.771)
28. Xuhua Tang, Chunyan Yang, Ying Gu, Cuiling Song, Xiao Zhang, Yingbin Wang, Jun Zhang, Choy Leong Hew, Shaowei Li*, Ningshao Xia*, and J. Sivaraman*. Structural basis for the neutralization and genotype specificity of hepatitis E virus. P NATL ACAD SCI USA 2011,25(108):10266-10271 (IF=9.771)
29. Zhu FC#, Zhang J#, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang QA, Yao X, Yan QA, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JWK, Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895-902. (IF=33.633)

荣誉、奖励及参加学术团体的情况:

国家技术发明二等奖
国家科技进步二等奖
中国专利金奖
全国创新争先奖
全国抗击新冠肺炎疫情先进集体
求是杰出科技成就集体奖
转化医学杰出贡献奖等奖励